CND Life Sciences: Funding, Investors & Team (Sep 2026)
CND Life Sciences is committed to supporting patients with neurodegenerative diseases, offering the Syn-One Test® as a first-of-its-kind tool to detect and measure misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. This test helps confirm synucleinopathies like Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. The company operates a CLIA-certified and CAP-accredited lab in Scottsdale, AZ, providing a convenient and accurate alternative for diagnosis through skin biopsies. Additionally, CND collaborates with biopharmaceutical companies to advance research in the field.
CND Life Sciences has raised $28.1M across 7 funding rounds on record, the most recent a Private Equity announced in Aug 2026.
CND Life Sciences Company Profile and Key Stats
Latest funding round on record: Aug 2026.
CND Life Sciences Funding Rounds
1 of 7 rounds was announced without a disclosed amount and is excluded from the total.
CND Life Sciences raised $2.4M in a Grant announced in May 2022.
5 months later, a Grant of $3.0M was announced in Oct 2022.
1.4 years later, an undisclosed round of $2.0M was announced in Mar 2024.
8 months later, an undisclosed round of $4.2M was announced in Nov 2024.
6 months later, a Series A of $13.5M was announced in May 2025.
5 months later, an undisclosed round of $3.0M was announced in Oct 2025.
10 months later, a Private Equity was announced in Aug 2026 with no disclosed amount.
CND Life Sciences Investors
16 investors are recorded in total; the 5 named above are those the record identifies.
CND Life Sciences Founders and Leadership Team
Contact details for the CND Life Sciences team: 5 of 5 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →CND Life Sciences Funding Compared to Other Biotechnology Startups
Funded Startups Like CND Life Sciences in Biotechnology and Scottsdale
Companies Similar to CND Life Sciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
CND Life Sciences Funding FAQs
What does CND Life Sciences do?
CND Life Sciences is committed to supporting patients with neurodegenerative diseases, offering the Syn-One Test® as a first-of-its-kind tool to detect and measure misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. This test helps confirm synucleinopathies like Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. The company operates a CLIA-certified and CAP-accredited lab in Scottsdale, AZ, providing a convenient and accurate alternative for diagnosis through skin biopsies. Additionally, CND collaborates with biopharmaceutical companies to advance research in the field.
How much funding has CND Life Sciences raised?
CND Life Sciences has raised $28.1M across 7 rounds on record.
When did CND Life Sciences last raise funding?
CND Life Sciences' most recent funding round on record was announced in Aug 2026. The amount was not disclosed.
Who has invested in CND Life Sciences?
Investors on record for CND Life Sciences include Michael J. Fox Foundation, LabCorp, MBX Capital, National Institutes of Health, BlueStone Venture Partners. FundedIQ records 16 investors in total.
Who founded CND Life Sciences?
FundedIQ lists Christopher Gibbons (Founder), Roy Freeman (Founder), Todd Dylan Levine (Founder) at CND Life Sciences.
Who is the CEO of CND Life Sciences?
Rick Morello is listed as Chief Executive Officer at CND Life Sciences.
Where is CND Life Sciences headquartered?
CND Life Sciences is based in Scottsdale, Arizona, United States.
How many employees does CND Life Sciences have?
CND Life Sciences is in the 11-50 employee band.
When was CND Life Sciences founded?
CND Life Sciences was founded in 2017.
About FundedIQ's CND Life Sciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CND Life Sciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.